This meeting builds on the successful conference held in 2011 and will highlight novel laboratory approaches, innovative pre-clinical science and the latest clinical trial results. The conference will include sessions on emerging developments, pre-clinical modelling, the role of host-immune response, approaches to trialling targeted drug combinations and strategies for clinical management of triple negative breast cancer. The aim is to advance our understanding of the aetiology, diagnosis and treatment of this challenging disease.
Hang on in there triple negsters things are happening ...........
Moondog xxx